BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38360853)

  • 1. Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year.
    Gingerich MC; Nair N; Azevedo JF; Samanta K; Kundu S; He B; Gomes-Solecki M
    NPJ Vaccines; 2024 Feb; 9(1):33. PubMed ID: 38360853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted
    Gingerich MC; Nair N; Azevedo JF; Samanta K; Kundu S; He B; Gomes-Solecki M
    Res Sq; 2023 Jul; ():. PubMed ID: 37503102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tick-Tattoo: DNA Vaccination Against
    Klouwens MJ; Trentelman JJA; Wagemakers A; Ersoz JI; Bins AD; Hovius JW
    Front Immunol; 2021; 12():615011. PubMed ID: 33717102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
    Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
    PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
    Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
    Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.
    Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA
    Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating BB0405 as a novel Borrelia afzelii vaccination candidate in Lyme borreliosis.
    Klouwens MJ; Trentelman JJ; Ersoz JI; Nieves Marques Porto F; Sima R; Hajdusek O; Thakur M; Pal U; Hovius JW
    Sci Rep; 2021 Feb; 11(1):4775. PubMed ID: 33637813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
    Comstedt P; Schüler W; Meinke A; Lundberg U
    PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs.
    Scheckelhoff MR; Telford SR; Hu LT
    Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of horses with Lyme vaccines for dogs induces short-lasting antibody responses.
    Guarino C; Asbie S; Rohde J; Glaser A; Wagner B
    Vaccine; 2017 Jul; 35(33):4140-4147. PubMed ID: 28668566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
    Eschner AK; Mugnai K
    Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates.
    Xiao P; Dienger-Stambaugh K; Chen X; Wei H; Phan S; Beavis AC; Singh K; Adhikary NRD; Tiwari P; Villinger F; He B; Spearman P
    Front Immunol; 2021; 12():623996. PubMed ID: 33717130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
    Grosenbaugh DA; Rissi DR; Krimer PM
    Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses.
    Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH
    Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development of a Rabies Virus-Vectored Vaccine against
    Rios S; Bhattachan B; Vavilikolanu K; Kitsou C; Pal U; Schnell MJ
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants.
    Beavis AC; Li Z; Briggs K; Huertas-Díaz MC; Wrobel ER; Najera M; An D; Orr-Burks N; Murray J; Patil P; Huang J; Mousa J; Hao L; Hsiang TY; Gale M; Harvey SB; Tompkins SM; Hogan RJ; Lafontaine ER; Jin H; He B
    bioRxiv; 2022 Jun; ():. PubMed ID: 35702147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.